Texas University Podcasts Texas University RSS feedThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

The importance of Doctor-Patient interaction
Elias Jabbour, MD from University of Texas MD Anderson Cancer Center, Houston, USA talks about a Doctor-Patient interaction. Working together with your doctor and making informed decisions is importan... Author: PatientPowerEU Added: 03/04/2016 (Source: Oncology Tube)
Source: Oncology Tube - March 4, 2016 Category: Cancer & Oncology Source Type: podcasts

Diagnostic tests for ALL
Elias Jabbour, MD from University of Texas MD Anderson Cancer Center, Houston, USA discusses tests used to diagnose ALL. Blood tests, bone marrow aspiration and exam looking for specific cancer marker... Author: PatientPowerEU Added: 03/04/2016 (Source: Oncology Tube)
Source: Oncology Tube - March 4, 2016 Category: Cancer & Oncology Source Type: podcasts

CAR T-cells - a new treatment option for ALL
Elias Jabbour, MD from University of Texas MD Anderson Cancer Center, Houston, USA gives a brief overview of CAR T-cells which are patient's own T-cells engineered in a laboratory to cure cancer. The ... Author: PatientPowerEU Added: 03/04/2016 (Source: Oncology Tube)
Source: Oncology Tube - March 4, 2016 Category: Cancer & Oncology Source Type: podcasts

Progress in treatment options for precursor B-cell ALL
Elias Jabbour, MD from University of Texas MD Anderson Cancer Center, Houston, USA discusses a study for precursor B-cell ALL presented at ASH 2015 where a combination of chemotherapy with rituximab s... Author: PatientPowerEU Added: 03/04/2016 (Source: Oncology Tube)
Source: Oncology Tube - March 4, 2016 Category: Cancer & Oncology Source Type: podcasts

How to treat the immature B-cell ALL (Burkitt disease)?
Elias Jabbour, MD from University of Texas MD Anderson Cancer Center, Houston, USA discusses treatment options for the immature B-cell ALL also known as Burkitt disease. An intensive chemotherapy trea... Author: PatientPowerEU Added: 03/04/2016 (Source: Oncology Tube)
Source: Oncology Tube - March 4, 2016 Category: Cancer & Oncology Source Type: podcasts

ALL subset identification for better treatment outcomes
Elias Jabbour, MD from University of Texas MD Anderson Cancer Center, Houston, USA talks about the importance of ALL subset identification. Thanks to the subset identification patient outcomes can be ... Author: PatientPowerEU Added: 03/04/2016 (Source: Oncology Tube)
Source: Oncology Tube - March 4, 2016 Category: Cancer & Oncology Source Type: podcasts

Treatment outcome prognosis in paediatric vs elderly ALL
Elias Jabbour, MD from University of Texas MD Anderson Cancer Center, Houston, USA gives a brief overview of Acute Lymphoblastic Leukaemia (ALL) and talks about outcome prognosis in paediatric vs elde... Author: PatientPowerEU Added: 03/04/2016 (Source: Oncology Tube)
Source: Oncology Tube - March 4, 2016 Category: Cancer & Oncology Source Type: podcasts

Acute leukemia: epidemiology and progress in treatment
Elias Jabbour, MD from the University of Texas MD Anderson Cancer Center, Houston, TX talks about the different forms of acute leukemia, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (... Author: VJHemOnc Added: 03/01/2016 (Source: Oncology Tube)
Source: Oncology Tube - March 1, 2016 Category: Cancer & Oncology Source Type: podcasts

Inotuzumab ozogamicin for the treatment of elderly acute lymphoblastic leukemia
Elias Jabbour, MD from the University of Texas MD Anderson Cancer Center, Houston, TX talks about a Phase II clinical trial of inotuzumab ozogamicin in elderly acute lymphoblastic leukemia patients, p... Author: VJHemOnc Added: 03/01/2016 (Source: Oncology Tube)
Source: Oncology Tube - March 1, 2016 Category: Cancer & Oncology Source Type: podcasts

Mechanism of action of venetoclax (ABT-199) adn its side-effects
William Wierda, MD, PhD from the University of Texas MD Anderson Cancer Center, Houston, TX talks about venetoclax (ABT-199), which is a Bcl-2 inhibitor. Bcl-2 is an apoptosis regulator expressed in h... Author: VJHemOnc Added: 02/26/2016 (Source: Oncology Tube)
Source: Oncology Tube - February 26, 2016 Category: Cancer & Oncology Source Type: podcasts

The side-effects profile of novel drugs in chronic lymphocytic leukemia
William Wierda, MD, PhD from the University of Texas MD Anderson Cancer Center, Houston, TX discusses the side-effects profile of novel drugs in chronic lymphocytic leukemia (CLL), presented at the Am... Author: VJHemOnc Added: 02/26/2016 (Source: Oncology Tube)
Source: Oncology Tube - February 26, 2016 Category: Cancer & Oncology Source Type: podcasts

Importance of prognostic factors in the treatment of CLL and how to assess them
William Wierda, MD, PhD from the University of Texas MD Anderson Cancer Center, Houston, TX talks about the importance of prognostic factors in the treatment of chronic lymphocytic leukemia (CLL). The... Author: VJHemOnc Added: 02/26/2016 (Source: Oncology Tube)
Source: Oncology Tube - February 26, 2016 Category: Cancer & Oncology Source Type: podcasts

Advances in the treatment of chronic lymphocytic leukemia
William Wierda, MD, PhD from the University of Texas MD Anderson Cancer Center, Houston, TX talks about recent advances in the treatment of chronic lymphocytic leukemia (CLL), presented at the America... Author: VJHemOnc Added: 02/26/2016 (Source: Oncology Tube)
Source: Oncology Tube - February 26, 2016 Category: Cancer & Oncology Source Type: podcasts

What are the options if the first treatment does not work?
At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, Dr Susan O’Brien, Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer, explains that... Author: PatientPowerEU Added: 01/26/2016 (Source: Oncology Tube)
Source: Oncology Tube - January 26, 2016 Category: Cancer & Oncology Source Type: podcasts

How do we know that chemotherapy for AML is working?
At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, Dr Susan O’Brien, Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer, explains that... Author: PatientPowerEU Added: 01/26/2016 (Source: Oncology Tube)
Source: Oncology Tube - January 26, 2016 Category: Cancer & Oncology Source Type: podcasts